Cipla launches Spirofy to treat chronic obstructive pulmonary disorder and asthma

Strengthens its lung leadership position by facilitating early diagnosis for COPD and asthma

0
53
Cipla
Spirofy - India's first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD) and asthma. photo biospectrum

Cipla announced the launch of Spirofy, India’s first pneumotach-based portable, wireless spirometer, on World COPD Day. With this launch, the company intends to revolutionize Obstructive Airway Disease (OAD) diagnosis, in line with its ambition to strengthen its position as the lung leader in India. This is a part of the company’s LungAttack campaign that endeavors to drive awareness about COPD and encourage early diagnosis.

Cipla’s Spirofy is a result of 5 years of meticulous in-house research by the Integrated Product Development (IPD) team, and it aims to transform Obstructive Airway Disease (OAD) diagnosis in India. This advanced device ensures high result accuracy and individual patient safety using Bacterial Viral Filters. 

Spirofy is entirely wireless with good battery backup, making it suitable for use in outdoor camps, remote areas with power shortages, or simply providing physicians’ flexibility and ease of use. The device generates reports in real-time, which can be printed using a portable wireless thermal printer instantly, or a pdf version can be shared on the phone. Cipla will undertake the training of physicians in the interpretation of spirometry results.

Cipla’s Spirofy aims to help doctors in improving the lungs of patients

Spirometry is the gold standard for COPD diagnosis. However, due to the bulky size, complex functionality, and need for regular maintenance, some reasons impacted medical practitioners’ widespread acceptance of conventional spirometers. This resulted in under diagnosis or misdiagnosis of COPD cases in India. Currently, COPD remains the second most common cause of death in India after heart diseases, where India alone bears 32% of the global COPD burden.

Commenting on the launch, Umang Vohra, managing director, and global chief executive officer, Cipla, said, “Cipla has been steadfastly focused on addressing the world’s growing respiratory disease burden, and with this launch, we see ourselves steadily advancing to combat chronic respiratory ailments like COPD. The Spirofy launch aims to help doctors across the country to improve the lives of patients through accurate and affordable diagnosis.”

Over the last six decades, Cipla relentlessly worked to improve access to life-saving drugs across the care continuum and provided a wide range of drug-device combinations to improve the lung health of millions of people in India and other key emerging markets.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here